Clinical trials located in

Plymouth

Plymouth city is located in United Kingdom. Currently, 20 clinical trials are being conducted in this city.

Plymouth, a port city on the south coast of Devon, England, boasts a rich maritime history. It is famously known as the departure point of the Mayflower in 1620, carrying Pilgrims to the New World. The city was heavily bombed during World War II, leading to extensive post-war rebuilding. Plymouth Hoe, a historic public space, offers panoramic views of Plymouth Sound, where the Royal Navy has a significant presence. The city also houses the University of Plymouth, contributing to its vibrant cultural scene.

  • CT-EU-00118701

    Study on SAGE-718 for improving cognitive function in Huntington’s disease

    This study focuses on Huntington’s Disease and aims to evaluate the effect of SAGE-718 on cognitive performance and functioning. Huntington’s Disease is a genetic disorder that affects the brain and leads to cognitive decline and motor dysfunction. The study will involve the drug SAGE-718 and a placebo. The primary goal is to understand how SAGE-718 impacts cognitive abilities in participants with Huntington’s Disease over 84 days. Participants will be randomly assigned to receive either the drug or a placebo daily, and their cognitive performance will be assessed using various tests.

    • SAGE-718
    • placebo
  • Study of a new anticancer vaccine (SCIB1) in combination with immunotherapeutic drugs in the treatment of malignant melanoma

    The aim of this clinical trial is to test whether a new cancer vaccine called SCIB1 can be safely used with two approved treatments for advanced melanoma – nivolumab (Opdivo) plus ipilimumab (Yervoy) or pembrolizumab (Keytruda). The study will also examine whether adding SCIB1 to these therapies can increase the chances of melanoma responding to treatment and the duration of that response.

    Currently, SCIB1 is still considered experimental, but has been previously administered to melanoma patients and was well tolerated. Scientists have even seen some signs that it may help stimulate the immune system to fight cancer. In this study, SCIB1 will be administered up to 10 times over 85 weeks by injection into the arm or leg using a special needle-free device. Before starting treatment, you will undergo several screening tests to make sure you are eligible to take part.

    • SCIB1 DNA vaccine
  • Testing a new drug for advanced prostate cancer

    This trial compares a new drug called AZD5305 with a placebo in men who have a specific kind of prostate cancer that has not responded to usual treatment methods. It’s a large trial, with around 1800 participants, and the main aim is to see whether the new treatment can help slow down the disease for longer than current treatments. Participants will be assigned to two different groups, and they will not know whether they’re receiving the real drug or the placebo. Their health will be monitored closely, with regular scans to check the progress of the cancer. The trial will also look at any side effects of the treatment and how it affects the patients’ ability to do their daily activities.

    • Enzalutamide/Xtandi
    • Darolutamide/Nubequa
    • Abiraterone Acetate/Zytiga
    • Saruparib
  • Testing the effectiveness of new drugs in the treatment of age-related macular degeneration

    The study is investigating a potential breakthrough in treating age-related vision loss, specifically neovascular age-related macular degeneration (nAMD). It introduces a novel therapy, OPT-302, and pairs it with Aflibercept, comparing this combination’s effectiveness against the standard treatment. Participants undergo a series of thorough eye examinations and treatments to monitor the progression of their vision health. The research aims to offer a clearer understanding of how these treatments can better manage and possibly improve vision for individuals dealing with nAMD, contributing valuable knowledge to the field of eye health care.

    • aflibercept
    • OPT-302
  • Investigating efficacy and safety of new therapy in early-stage Parkinson’s disease

    This clinical trial aims to examine BIIB122, a new medication considered to potentially slow down the progression of early-stage Parkinson’s disease in patients aged between 30–80 years old. Participants will undergo treatment with either BIIB122 or a placebo equal in appearance but devoid of actual medicine. The trial’s routine includes a single daily medication intake for a timeframe between 48 and 144 weeks. To evaluate the medication’s efficacy, patients’ symptoms and their impact on everyday life will be observed using the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS). In addition to this, safety assessment of BIIB122 will be a main focus of the study. The trial treats this as a double-blind study, anonymizing whether a patient takes the BIIB122 drug or a placebo.

    • BIIB122
  • Exploring the safety of seladelpar in treating primary biliary cholangitis

    This is a long-term study on a drug named seladelpar for people with a liver disease called Primary Biliary Cholangitis (PBC). The main goal is to see if this drug is safe and easy for patients with PBC to use over a long period. A secondary goal is to see if seladelpar can effectively treat PBC and improve the patient’s quality of life. The study will track a few things, like if there are changes in the patient’s liver health which may lead to hospitalization or if the patient’s liver enzymes like alkaline phosphate and bilirubin level normalize or not after taking this drug.

    • Seladelpar
  • New therapy trial for relapsed large B-cell lymphoma

    This study is testing the use of two different treatments for diffuse large B-cell lymphoma (DLBCL), a type of blood cancer. Group One receives a mix of drugs, including polatuzumab vedotin, rituximab, ifosfamide, carboplatin, and etoposide (collectively called Pola-R-ICE). Group Two receives a similar mix without polatuzumab vedotin, known as R-ICE. Patients will be randomly sorted into the two groups. The test treatment spans three months and includes three chemotherapy treatments. After that, doctors will follow up with patients for at least 21 months. The goal is to compare how well the two treatments work to control DLBCL. Different factors, like progress of the disease, the response to treatment, and overall health will be observed to determine how efficient these treatments are.

    • Mabthera
    • Ifosfamide
    • Polatuzumab vedotin
    • Etoposide
    • Carboplatin
  • Study on the efficacy of pirtobrutinib for mantle cell lymphoma

    This clinical trial is designed for patients diagnosed with mantle cell lymphoma (MCL), a type of blood cancer. The primary objective of the study is to assess the efficacy of a new drug called pirtobrutinib in comparison to other similar drugs that have received approval from the U.S. Food and Drug Administration (FDA). Participants may be involved in the study for a duration of two years or more, contingent on their condition not worsening. The trial will categorize patients into two groups: one receiving pirtobrutinib, and the other receiving either ibrutinib, acalabrutinib, or zanubrutinib, which are existing FDA-approved drugs for this condition. Throughout the study, the participants’ health condition, symptoms, and any side effects will be closely monitored. Additionally, the effectiveness of the treatments will be measured by evaluating the eventual survival rates of the patients.

    • Pirtobrutinib/LOXO-305
    • Zanubrutinib
    • Ibrutinib
    • Acalabrutinib
  • Research on medicine combination for B-cell Non-Hodgkin Lymphoma

    This study is about testing epcoritamab, a new drug for a type of blood cancer called B-cell Non-Hodgkin Lymphoma. The goal is to see if the drug is safe for people and can successfully fight the cancer. Doctors will combine this drug with other medicines that are typically used to treat this cancer. The combined treatment will vary for different groups of patients, depending on factors like their specific type of cancer or their overall health. Some patients will be given epcoritamab on its own, while others will receive it with other cancer medicines. The study has two parts. The first part is to find a safe dose of the drug. The second part is to determine how well this drug helps in treating the cancer. Side effects will be closely monitored during the study.

    • etoposide phosphate
    • oxaliplatin
    • Prednisone
    • Dexamethasone
    • Carboplatin
    • Epcoritamab
    • Ifosfamide
    • Cytarabine
    • Gemcitabine
    • Cyclophosphamide
    • Vincristine
    • Doxorubicin
    • Bendamustine
    • Lenalidomide
    • Rituximab
  • Acalabrutinib, venetoclax and rituximab combination for newly diagnosed mantle cell lymphoma

    This clinical trial explores a new drug combination for treating mantle cell lymphoma in patients who have not received prior treatments. The study involves acalabrutinib, venetoclax, and rituximab (AVR) and aims to determine their effectiveness in achieving a minimal residual disease-negative complete response after 13 cycles of treatment. Patients achieving this response will be randomly assigned to continue acalabrutinib or enter observation. The study’s goal is to assess the efficacy and safety of the AVR combination in newly diagnosed mantle cell lymphoma patients.

    • Acalabrutinib
    • Rituximab
    • Venetoclax
  • Comparing favezelimab/pembrolizumab combo with standard chemotherapy for Hodgkin lymphoma

    This study is investigating a treatment for PD-(L)1-refractory, relapsed, or refractory classical Hodgkin lymphoma, a type of blood cancer. Researchers are evaluating a new drug combination known as MK-4280A (favezelimab/pembrolizumab) alongside standard drugs typically used for this condition (bendamustine or gemcitabine). The aim is to determine if MK-4280A is superior to the standard drugs in extending patients’ lifespan and slowing down disease progression. Additionally, scientists will assess the safety and tolerability of MK-4280A during the study, noting any potential side effects of the drug.

    • Favezelimab
    • Pembrolizumab
    • Bendamustine
    • Gemcitabine
  • Testing new medication on adults with advanced lymphoma

    This is a study in two parts for adults who have certain forms of lymphomas, a kind of blood cancer. Researchers are testing a drug called STP938. Phase 1 is about finding out the best dose that can be given safely to the patients. Phase 2 will see if the drug works well in treating different kinds of lymphomas.STP938 works by blocking an enzyme named cytidine triphosphate synthase 1 (CTPS1). This enzyme plays a part in creating DNA and RNA, the elements required for cell division. In certain blood cells, its blockage can prevent their rapid multiplication, which could help in fighting against lymphomas. Patients will be given STP938 in tablet form. Doctors will take their blood samples during the study to understand the effects of the drug on lymphoma and other parts of the body. The goal is to check if STP938 can be used safely, at what dose, and see if it’s effective in treating lymphoma. This study will also track the time it takes for the drug to respond, how long the response lasts, and the overall health changes during treatment.

    • STP938- new potential medication for hematological malignancies
  • New potential drug evaluation in cholestatic pruritus

    This study aims to assess the effectiveness of the potential new drug-EP547 in alleviating cholestatic pruritus among individuals aged 18 to 80 with Primary Biliary Cholangitis (PBC) or Primary Sclerosing Cholangitis (PSC). Inclusion criteria involve documented diagnoses of PBC or PSC, the presence of moderate to severe pruritus, and acceptance of specific anti-pruritic and anti-cholestatic medications. Exclusion criteria include pruritus unrelated to PBC or PSC, a history of liver transplantation, cirrhosis, alternative liver diseases, secondary sclerosing cholangitis, significant strictures or biliary stents, small bowel resection, and certain laboratory results indicating ineligibility.

    • EP547- new potential medication for cholestatic and uremic pruritus
  • Comparing treatments in multiple myeloma: talquetamab in combination with other medication

    This study aims to explore the combined effects of talquetamab, daratumumab, pomalidomide, and dexamethasone for treating relapsed or refractory multiple myeloma. One group of patients will receive talquetamab subcutaneous in combination with daratumumab and pomalidomide. The second group will receive talquetamab subcutaneous in combination with daratumumab. The patients of the third group will be treated with daratumumab subcutaneous in combination with pomalidomide and dexamethasone. The research is divided into three phases: screening, treatment, and post-treatment follow-up. The study will assess efficacy, safety, and monitoring various health indicators at specific time points. The results of this combination therapy will be compared to choose the safest and the most effective treatment. The overall duration of the study is expected to be up to 6 years and 6 months.

    • Pomalidomide
    • Talquetamab
    • Dexamethasone
    • Daratumumab
  • Study on risk reduction of heart complications with Milvexian

    This study involves a drug called milvexian, which is being tested for people who have recently experienced a heart-related episode, like a heart attack or stroke (acute coronary syndrome). Half of the participants will receive milvexian, and the other half will get a placebo. The study’s main aim is to show that milvexian can help reduce the chance of major heart-related problems happening again. These problems include things like heart failure, another heart attack, or an ischemic stroke.

    • Milvexian
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    • Zanubrutinib
    • Obinutuzumab
    • Lenalidomide
    • Rituximab
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    • Dazostinag
    • Platinum
    • Pembrolizumab
    • 5-Fluorouracil
  • Inhaler treatment study for Mycobacterium Avium complex lung infection

    This study is for adults with lung infections caused by Mycobacterium avium complex. It tests a new inhalation treatment, ALIS (amikacin liposome inhalation suspension), in combination with standard drugs, azithromycin and ethambutol. The aim is to see if ALIS improves respiratory symptoms better than the standard treatment alone. Participants will receive either ALIS or a placebo, along with the standard drugs. The study focuses on safety, symptom improvement, and overall health impact. This research is important for finding more effective treatments for these challenging lung infections.

    • ALIS (amikacin liposome inhalation suspension)
    • Azithromycin
    • Ethambutol
  • New drug trial for long-term control of hepatitis B

    This study focuses on the long-term effects of GSK3228836 in patients with hepatitis B. It assesses the durability of the drug’s effectiveness, specifically how long patients maintain a sustained virological response (SVR) after treatment. The study will involve two groups: people who have not previously used Nucleos(t)ide (NA) analogue therapy and people controlled by NA therapy. Participants will be monitored for re-emergence of the hepatitis B virus and the need for additional treatment. The study aims to gain insight into the long-term effectiveness of GSK3228836 in the treatment of hepatitis B virus infection.

    • bepirovirsen 
  • Evaluating itch relief in liver disease with linerixibat

    The GLISTEN study is a detailed research project exploring the effectiveness of a medication called linerixibat in treating severe itching in people with a liver condition known as Primary Biliary Cholangitis (PBC). In this study, participants are given either linerixibat or a placebo to see which one better reduces itching and improves sleep and overall quality of life. This research is important for finding new ways to help people with PBC who experience discomfort from itching.

    • Linerixibat

See more clinical trials in other cities in United Kingdom:

.